Search results for "Continuation"

showing 6 items of 276 documents

Quantitative Approximation Properties for the Fractional Heat Equation

2017

In this note we analyse \emph{quantitative} approximation properties of a certain class of \emph{nonlocal} equations: Viewing the fractional heat equation as a model problem, which involves both \emph{local} and \emph{nonlocal} pseudodifferential operators, we study quantitative approximation properties of solutions to it. First, relying on Runge type arguments, we give an alternative proof of certain \emph{qualitative} approximation results from \cite{DSV16}. Using propagation of smallness arguments, we then provide bounds on the \emph{cost} of approximate controllability and thus quantify the approximation properties of solutions to the fractional heat equation. Finally, we discuss genera…

osittaisdifferentiaaliyhtälöt0209 industrial biotechnologyClass (set theory)Control and Optimizationfractional parabolic Calderón problemPseudodifferential operatorsApplied Mathematics010102 general mathematics02 engineering and technologyType (model theory)nonlocal operators [cost of approximation]01 natural sciencesinversio-ongelmatControllabilityMathematics - Analysis of PDEsweak unique continuation [Runge approximation]020901 industrial engineering & automationFOS: MathematicsApplied mathematicsHeat equationapproksimointi0101 mathematicsMathematicsAnalysis of PDEs (math.AP)
researchProduct

Partial Data Problems and Unique Continuation in Scalar and Vector Field Tomography

2022

AbstractWe prove that if P(D) is some constant coefficient partial differential operator and f is a scalar field such that P(D)f vanishes in a given open set, then the integrals of f over all lines intersecting that open set determine the scalar field uniquely everywhere. This is done by proving a unique continuation property of fractional Laplacians which implies uniqueness for the partial data problem. We also apply our results to partial data problems of vector fields.

osittaisdifferentiaaliyhtälötvector field tomographyinverse problemstomografiaApplied MathematicsGeneral MathematicsX-ray tomographyregion of interest tomographyunique continuationinversio-ongelmatAnalysisJournal of Fourier Analysis and Applications
researchProduct

The Continuation War as a metanoic moment : a Burkean reading of lutheran hierocratic rhetoric

2012

rhetoricmetanoiapapitretoriikkapolitiikkasotapapistojatkosotaContinuation Warsymbolic actionclergyteologiapoliittisuusBurke Kennethuskonto
researchProduct

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

2017

ObjectiveOur aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.MethodsWe conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI95%) were calculated.ResultsSix RCTs were eligible (mino…

safetymedicine.medical_specialtyefficacyMinocyclinePlacebometa-analysi03 medical and health sciences0302 clinical medicinesystematic reviewInternal medicineefficacy; meta-analysis; Minocycline; safety; schizophrenia; systematic review; Neurology (clinical); Psychiatry and Mental HealthMedicineHumansRandomized Controlled Trials as TopicPositive and Negative Syndrome Scalebusiness.industryMinocycline schizophrenia efficacy safety meta-analysis systematic reviewConfidence interval030227 psychiatryDiscontinuationAnti-Bacterial Agentsmeta-analysisschizophreniaTolerabilityStrictly standardized mean differencePsychiatry and Mental HealthMeta-analysisAdjunctive treatmentNeurology (clinical)business030217 neurology & neurosurgeryAntipsychotic Agents
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct